CA2343916A1 - Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques - Google Patents

Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques Download PDF

Info

Publication number
CA2343916A1
CA2343916A1 CA002343916A CA2343916A CA2343916A1 CA 2343916 A1 CA2343916 A1 CA 2343916A1 CA 002343916 A CA002343916 A CA 002343916A CA 2343916 A CA2343916 A CA 2343916A CA 2343916 A1 CA2343916 A1 CA 2343916A1
Authority
CA
Canada
Prior art keywords
agent
antibody
factor viii
cell
costimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002343916A
Other languages
English (en)
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American National Red Cross
Genetics Institute LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2343916A1 publication Critical patent/CA2343916A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des méthodes permettant de traiter des troubles hémostatiques au moyen d'agents stimulant l'hémostase et d'agents inhibant un signal costimulant dans un lymphocyte T. Les compositions et méthodes selon l'invention permettent de traiter les troubles hémostatiques au moyen de protéines thérapeutiques étrangères, tout en exerçant une modulation restrictive des réponses immunitaires à ces protéines thérapeutiques.
CA002343916A 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques Abandoned CA2343916A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
US09/158,178 1998-09-21
PCT/US1999/021991 WO2000016801A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques

Publications (1)

Publication Number Publication Date
CA2343916A1 true CA2343916A1 (fr) 2000-03-30

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002343916A Abandoned CA2343916A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques

Country Status (21)

Country Link
EP (1) EP1115423A1 (fr)
JP (1) JP2002526455A (fr)
KR (1) KR20010085830A (fr)
CN (1) CN1331602A (fr)
AU (1) AU761206B2 (fr)
BR (1) BR9913991A (fr)
CA (1) CA2343916A1 (fr)
CZ (1) CZ20011021A3 (fr)
EA (1) EA005236B1 (fr)
HK (1) HK1039059A1 (fr)
HU (1) HUP0103960A3 (fr)
IL (1) IL142069A0 (fr)
LT (1) LT4920B (fr)
LV (1) LV12768B (fr)
MX (1) MXPA01002898A (fr)
NO (1) NO20011412L (fr)
NZ (1) NZ511034A (fr)
PL (1) PL346796A1 (fr)
SI (1) SI20626A (fr)
WO (1) WO2000016801A1 (fr)
ZA (1) ZA200103156B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO2001089564A2 (fr) * 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Procedes pour diagnostiquer et traiter des troubles hemostatiques par modulation de l'activite de la p-selectine
JP2007516509A (ja) * 2003-06-10 2007-06-21 スミスズ ディテクション インコーポレイティド センサ装置
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3722375B2 (ja) 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
WO1993009804A1 (fr) 1991-11-18 1993-05-27 The Scripps Research Institute Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP0776217A1 (fr) * 1994-08-19 1997-06-04 Novo Nordisk A/S Methode de traitement d'un patient a l'aide d'un compose biologiquement actif
EP0804076A4 (fr) * 1994-10-19 1998-10-21 Genetic Therapy Inc Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l
BR9810755A (pt) * 1997-06-20 2000-08-15 Biogen Inc Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica
US8151477B2 (en) 2009-11-06 2012-04-10 Hexagon Metrology Ab CMM with modular functionality

Also Published As

Publication number Publication date
WO2000016801A1 (fr) 2000-03-30
EP1115423A1 (fr) 2001-07-18
CN1331602A (zh) 2002-01-16
HUP0103960A3 (en) 2003-09-29
LV12768A (en) 2001-12-20
EA200100385A1 (ru) 2001-10-22
NZ511034A (en) 2004-03-26
LT4920B (lt) 2002-06-25
HK1039059A1 (zh) 2002-04-12
AU761206B2 (en) 2003-05-29
WO2000016801A9 (fr) 2000-10-26
BR9913991A (pt) 2001-07-03
LT2001045A (en) 2002-01-25
JP2002526455A (ja) 2002-08-20
PL346796A1 (en) 2002-02-25
ZA200103156B (en) 2002-07-18
KR20010085830A (ko) 2001-09-07
NO20011412D0 (no) 2001-03-20
SI20626A (sl) 2002-02-28
HUP0103960A2 (hu) 2002-02-28
MXPA01002898A (es) 2002-06-04
IL142069A0 (en) 2002-03-10
AU6057899A (en) 2000-04-10
LV12768B (lv) 2002-06-20
CZ20011021A3 (cs) 2001-10-17
NO20011412L (no) 2001-05-16
EA005236B1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
Qian et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
Lollar Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
JP4052524B2 (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
US6451305B1 (en) Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand
US20120269806A1 (en) Methods of inducing tolerance
JP2012229271A (ja) 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
KR0183029B1 (ko) 내성을 유도하기 위한 모노클론 항체류
Saenko et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
Miao et al. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice
US20210355231A1 (en) Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
AU761206B2 (en) Methods of downmodulating the immune response to therapeutic proteins
US20070092506A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
US20030161827A1 (en) Therapies that improve graft survival
US20230382972A9 (en) Cd80 extracellular domain fc fusion protein regimens
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Bril Factor VIII inhibitors in mild haemophilia A
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
AU3437902A (en) Methods for modulating T cell unresponsiveness

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued